Literature DB >> 8103930

Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways.

T Pawson1, P Olivier, M Rozakis-Adcock, J McGlade, M Henkemeyer.   

Abstract

The targets of receptor protein-tyrosine kinases are characterized by Src homology 2 (SH2) domains, that mediate specific interactions with receptor autophosphorylation sites. SH2-mediated interactions are important for the activation of biochemical signalling pathways in cells stimulated with growth factors. A distinct protein module, the SH3 domain, is frequently found in polypeptides that contain SH2 domains, and is also implicated in controlling protein-protein interactions in signal transduction. Evidence suggesting that SH2 and SH3 domains act synergistically in stimulation of the Ras pathway is discussed.

Mesh:

Substances:

Year:  1993        PMID: 8103930     DOI: 10.1098/rstb.1993.0069

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  11 in total

Review 1.  Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.

Authors:  A Virkamäki; K Ueki; C R Kahn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

2.  Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.

Authors:  S Fruehling; S K Lee; R Herrold; B Frech; G Laux; E Kremmer; F A Grässer; R Longnecker
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

3.  Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase.

Authors:  L Ling; H J Kung
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

4.  Phosphoproteomics Analysis Identifies Novel Candidate Substrates of the Nonreceptor Tyrosine Kinase, Src-related Kinase Lacking C-terminal Regulatory Tyrosine and N-terminal Myristoylation Sites (SRMS).

Authors:  Raghuveera Kumar Goel; Marta Paczkowska; Jüri Reimand; Scott Napper; Kiven Erique Lukong
Journal:  Mol Cell Proteomics       Date:  2018-03-01       Impact factor: 5.911

5.  Prolactin receptor-integrin cross-talk mediated by SIRPα in breast cancer cells.

Authors:  Traci Galbaugh; Yvonne B Feeney; Charles V Clevenger
Journal:  Mol Cancer Res       Date:  2010-09-08       Impact factor: 5.852

6.  The characterization of Abelson helper integration site-1 in skeletal muscle and its links to the metabolic syndrome.

Authors:  Matthew J Prior; Victoria C Foletta; Jeremy B Jowett; David H Segal; Melanie A Carless; Joanne E Curran; Tom D Dyer; Eric K Moses; Andrew J McAinch; Nicky Konstantopoulos; Kiymet Bozaoglu; Greg R Collier; David Cameron-Smith; John Blangero; Ken R Walder
Journal:  Metabolism       Date:  2009-12-31       Impact factor: 8.694

7.  Phosphotyrosine signaling: evolving a new cellular communication system.

Authors:  Wendell A Lim; Tony Pawson
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

8.  Effect of cavtratin, a caveolin-1 scaffolding domain peptide, on oligodendroglial signaling cascades.

Authors:  Matthias Schmitz; Inga Zerr; Hans H Althaus
Journal:  Cell Mol Neurobiol       Date:  2011-04-27       Impact factor: 5.046

Review 9.  Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.

Authors:  David L Brautigan; Caroline Farrington; Goutham Narla
Journal:  Clin Sci (Lond)       Date:  2021-07-16       Impact factor: 6.876

10.  Manifold roles of β-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9.

Authors:  Louis M Luttrell; Jialu Wang; Bianca Plouffe; Jeffrey S Smith; Lama Yamani; Suneet Kaur; Pierre-Yves Jean-Charles; Christophe Gauthier; Mi-Hye Lee; Biswaranjan Pani; Jihee Kim; Seungkirl Ahn; Sudarshan Rajagopal; Eric Reiter; Michel Bouvier; Sudha K Shenoy; Stéphane A Laporte; Howard A Rockman; Robert J Lefkowitz
Journal:  Sci Signal       Date:  2018-09-25       Impact factor: 9.517

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.